Rhenman & Partners Asset Management’s Rigel Pharmaceuticals RIGL Stock Holding History

Rhenman & Partners Asset Management’s Portfolio RIGL Stock Details RIGL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-25,383	Closed	-$327K	–	87
2023 Q2	$327K	Sell	25,383 -90,376	-78%	-$1.22M	0.03%	82
2023 Q1	$1.55M	Sell	115,759 -6,749	-6%	-$107K	0.17%	79
2022 Q4	$1.84M	Hold	122,508	–	–	0.19%	85
2022 Q3	$893K	Hold	122,508	–	–	0.09%	89
2022 Q2	$1.38M	Sell	122,508 -5,269	-4%	-$106K	0.16%	84
2022 Q1	$3.82M	Sell	127,777 -24,223	-16%	-$656K	0.38%	71
2021 Q4	$4.07M	Hold	152,000	–	–	0.27%	78
2021 Q3	$5.52M	Hold	152,000	–	–	0.39%	72
2021 Q2	$6.6M	Hold	152,000	–	–	0.45%	72
2021 Q1	$5.2M	Sell	152,000 -21,618	-12%	-$856K	0.36%	73
2020 Q4	$6.08M	Hold	173,618	–	–	0.5%	61
2020 Q3	$4.17M	Hold	173,618	–	–	0.37%	67
2020 Q2	$3.18M	Hold	173,618	–	–	0.34%	74
2020 Q1	$2.71M	Sell	173,618 -16,382	-9%	-$349K	0.38%	69
2019 Q4	$4.07M	Sell	190,000 -10,000	-5%	-$206K	0.45%	67
2019 Q3	$3.74M	Sell	200,000 -26,494	-12%	-$547K	0.47%	63
2019 Q2	$5.91M	Hold	226,494	–	–	0.65%	56
2019 Q1	$5.82M	Hold	226,494	–	–	0.68%	56
2018 Q4	$5.21M	Buy	226,494 +15,095	+7%	+$426K	0.6%	56
2018 Q3	$6.79M	Buy	211,399 +41,071	+24%	+$1.23M	0.68%	57
2018 Q2	$4.82M	Buy	170,328 +8,551	+5%	+$304K	0.49%	61
2018 Q1	$5.73M	Sell	161,777 -31,506	-16%	-$1.26M	0.71%	52
2017 Q4	$7.5M	Sell	193,283 -41,717	-18%	-$1.59M	1.01%	41
2017 Q3	$5.97M	Buy	235,000 +97,410	+71%	+$2.37M	0.76%	51
2017 Q2	$3.76M	Buy	137,590 +9,390	+7%	+$257K	0.54%	66
2017 Q1	$4.24M	Hold	128,200	–	–	0.67%	56
2016 Q4	$3.05M	Sell	128,200 -11,800	-8%	-$338K	0.58%	63
2016 Q3	$5.14M	Buy	140,000 +55,000	+65%	+$1.58M	0.82%	46
2016 Q2	$1.9M	Hold	85,000	–	–	0.34%	77
2016 Q1	$1.77M	Buy	85,000 +569	+0.7%	+$14K	0.35%	78
2015 Q4	$2.56M	Sell	84,431 -8,069	-9%	-$245K	0.39%	76
2015 Q3	$2.29M	Hold	92,500	–	–	0.36%	75
2015 Q2	$2.97M	Sell	92,500 -7,500	-8%	-$287K	0.36%	83
2015 Q1	$3.57M	Buy	+100,000	New	+$2.74M	0.6%	56

Other funds holding RIGL

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Rhenman & Partners Asset Management's RIGL Position: Q3 2023 in Review

Rhenman & Partners Asset Management sold out of Rigel Pharmaceuticals (RIGL) in Q3 2023, closing a stake of 25,383 shares — an estimated $327K sold.

Rhenman & Partners Asset Management first reported a position in RIGL in Q1 2015 and held it in 34 quarters. The position peaked at $7.5M in Q4 2017. 106 funds tracked by Wall St. Rank hold RIGL as of Q3 2023.

Rhenman & Partners Asset Management reported no remaining Rigel Pharmaceuticals position as of Q3 2023 after selling out during the quarter.
Rhenman & Partners Asset Management sold 25,383 Rigel Pharmaceuticals shares in Q3 2023, an estimated $327K.
Rhenman & Partners Asset Management first reported a position in Rigel Pharmaceuticals in Q1 2015 and held it in 34 quarters.
Rhenman & Partners Asset Management's Rigel Pharmaceuticals position peaked at $7.5M in Q4 2017.
106 funds tracked by Wall St. Rank held Rigel Pharmaceuticals as of Q3 2023.

Based on Rhenman & Partners Asset Management's 13F filing for Q3 2023, filed 9 Nov 2023.